Table 4.
Risk Factors for Mortality by Day 28 and Day 90 in Solid Organ Transplant Recipients Hospitalized for Coronavirus Disease 2019, Multivariable Cox Proportional Hazards (N = 1117)
| Covariate | Mortality by 28 Days | Mortality by 90 Days |
|---|---|---|
| Adjusted Hazard Ratio (95% Confidence Interval), P Value | ||
| Age >65 years | 1.8 (1.3–2.6), <.001 | 1.8 (1.3–2.4), <.001 |
| Lung transplant (vs nonlung transplant) | 1.8 (1.1–2.8), .02 | 1.5 (1.0–2.3), .05 |
| Comorbidities a | ||
| Diabetes mellitus | 1.2 (.8–1.7), .34 | 1.3 (1.0–1.8), .09 |
| Heart failure | 1.9 (1.2–3.1), .01 | 1.9 (1.2–2.9), .006 |
| Chronic lung disease | 2.4 (1.5–3.7), <.001 | 2.3 (1.5–3.6), <.001 |
| Body mass index ≥30 kg/m2 | 1.6 (1.1–2.2), .01 | 1.5 (1.1–2.0), .02 |
| Baseline mammalian target of rapamycin inhibitor use | 0.3 (.1–1.0), .05 | 0.5 (.2–1.1), .07 |
| Late 2020 (on or after 20 June 2020) | 0.7 (.5–1.0), .04 | 0.9 (.7–1.3), .61 |
| Lymphopenia (absolute lymphocyte count <0.5 × 109/L) at presentation | 1.8 (1.3–2.6), <.001 | 1.8 (1.3–2.4), <.001 |
| Abnormal chest imaging at presentation | 2.9 (1.5–5.5), .002 | 2.7 (1.6–4.7), <.001 |
Statistically significant values (P ≤ .05) are shown in bold.